74256-73-8

Upstream product

• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 59-01-8 kanamycin A 

Downstream Products

• 533923-28-3 C₄₈H₆₀F₃N₅O₁₉ 
• 533923-43-2 C₄₉H₆₁F₃N₈O₂₀ 
• 533923-44-3 C₄₉H₆₁F₃N₈O₂₀ 
• 533923-18-1 C₅₄H₆₃F₃N₆O₂₁ 
• 533923-22-7 C₅₅H₆₅F₃N₆O₂₁ 
• 533923-19-2 C₅₅H₆₅F₃N₆O₂₁ 
• 533923-20-5 C₅₆H₆₇F₃N₆O₂₁ 
• 533923-21-6 C₅₇H₆₉F₃N₆O₂₁ 
• 533923-35-2 C₆₅H₈₀F₃N₅O₂₁Si 
• 533923-34-1 C₆₅H₈₀F₃N₅O₂₁Si 
• 81076-65-5 1-epi-kanamycin A 
• 80860-34-0 di-tert-butyl ((1S,3R,4S,5R,6R)-4-(((2S,3R,4S,5S,6R)-4-((tert-butoxycarbonyl)amino)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5S,6R)-6-(((tert-butoxycarbonyl)amino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)dicarbamate 
• 59-01-8 kanamycin A 

Relevant academic research and scientific papers

Covalently linked kanamycin – Ciprofloxacin hybrid antibiotics as a tool to fight bacterial resistance

To address the growing problem of antibiotic resistance, a set of 12 hybrid compounds that covalently link fluoroquinolone (ciprofloxacin) and aminoglycoside (kanamycin A) antibiotics were synthesized, and their activity was determined against both Gram-n

Conjugated antimicrobial agents

Provided herein are antimicrobial conjugates of two antibiotic agents, exhibiting improved activity also against resistant bacteria, compared to each of the agents separately or their mixture, and having substantially no resistance emerged thereagainst, as well as processes for preparation the same, compositions containing the same, and uses thereof in medical treatments against pathogenic microorganisms. The disclosed antimicrobial conjugates are composed of aminoglycosides and non-ribosomal active antibiotics. Some of the antimicrobial conjugates are prepared via “click” chemistry.

Probing the functional requirements of the L-haba side-chain of amikacin - Synthesis, 16S A-site rRNA binding, and antibacterial activity

The l-amino group in amikacin was acylated with a variety of 2-hydroxy aminocarboxylic acids to probe the effect of acylation on ribosomal binding and antibacterial activity. The N-hydroxy urea analogue of amikacin (8a) in which the 2-S-hydroxyl-bearing carbon was replaced by an N-OH group was equally active against S. aureus and E. coli in vitro. The analogous tobramycin variant 9 was more active than amikacin.